Influenza Vaccine Project at Birmex

Partnership objective

Manufacture influenza vaccine to meet the production need of seasonal and pandemic vaccine in Mexico. 

Influenza occurs annually, causing significant amount of disease and death, particularly in the elderly, young children and those with certain chronic conditions. Influenza occurs annually, causing significant amount of disease and death, particularly in the elderly, young children and those with certain chronic conditions. Copyright Sanofi Pasteur

What are the health needs and challenges?

Influenza occurs annually, causing significant amount of disease and death, particularly in the elderly, young children and those with certain chronic conditions.

The most common symptoms of the disease are chills, fever, sore throat, muscle pains, severe headache, coughing, weakness/fatigue and general discomfort. Although it is often confused with other influenza-like illnesses, especially the common cold, influenza is a more severe disease than the common cold and is caused by a different type of virus. Influenza can cause mild to severe illness, and at times can lead to death.

Influenza vaccines have been providing good levels of protection for more than 50 years. However, influenza vaccine production is highly complex and involves a large number of steps. 

Description of partnership activities and how they address needs and challenges

Sanofi Pasteur signed an agreement in 2009 with the Mexican government to build a EUR100 million facility to manufacture influenza vaccine in Mexico. This facility has been built and operated by Sanofi Pasteur, the vaccines division of Sanofi Group, which manufactures influenza vaccine there in collaboration with Birmex (Laboratorio de Biológicos y Reactivos de México), a vaccine manufacturer owned by the Mexican federal government. Birmex will perform certain stages of manufacturing as well as distribute influenza vaccines within Mexico. The facility, which has an annual capacity of up to 25 million doses of seasonal influenza vaccine, is able to switch to pandemic vaccine production, if required.

Partnership information

Company(ies) Sanofi

Partner(s) Laboratorios de Biológicos y Reactivos de México (BIRMEX), Mexican Ministry of Health

Type of Partner(s) Academia / Hospitals, Government

Therapeutic Focus Women and Children's Health, Vaccine-Preventable Diseases

Disease(s) Children's Health, Influenza

Program Type(s) Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Health System Infrastructure - Development of Physical Infrastructure, Prevention Programs - Vaccines

Targeted Population(s) Children, Elderly

Region(s) Latin America & Caribbean

Number of Countries 1

Country(ies) Mexico

Start Date 2009

More information Sanofi Pasteur

Anticipated completion date Ongoing